{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:15:54Z","timestamp":1790806554982,"version":"4.1.0"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13346-025-01903-y","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T12:59:43Z","timestamp":1750769983000},"page":"4043-4066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring multifaceted roles of metformin in therapeutic applications, mechanistic insights, and innovations in drug delivery systems across biological contexts: a systematic review"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3601-6306","authenticated-orcid":false,"given":"Nor Akmalyati","family":"Sulong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2911-7726","authenticated-orcid":false,"given":"Vannajan Sanghiran","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Chin","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Rafie","family":"Johan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"1903_CR1","doi-asserted-by":"crossref","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577\u201385.","DOI":"10.1007\/s00125-017-4342-z"},{"key":"1903_CR2","doi-asserted-by":"publisher","unstructured":"Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. 2014. https:\/\/doi.org\/10.1016\/j.cmet.2014.09.018.","DOI":"10.1016\/j.cmet.2014.09.018"},{"issue":"3","key":"1903_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2020.100656","volume":"46","author":"P Saeedi","year":"2021","unstructured":"Saeedi P, Cao Y, Fadl MM, Barakat R. Role of metformin in cardiovascular disease: evidence and mechanisms. Curr Probl Cardiol. 2021;46(3): 100656. https:\/\/doi.org\/10.1016\/j.cpcardiol.2020.100656.","journal-title":"Curr Probl Cardiol"},{"issue":"8","key":"1903_CR4","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00125-013-2924-8","volume":"56","author":"BM Heckman-Stoddard","year":"2013","unstructured":"Heckman-Stoddard BM, DeCensi A. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2013;56(8):1581\u20139. https:\/\/doi.org\/10.1007\/s00125-013-2924-8.","journal-title":"Diabetologia"},{"key":"1903_CR5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"G Zhou","year":"2001","unstructured":"Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167\u201374. https:\/\/doi.org\/10.1172\/JCI13505.","journal-title":"J Clin Invest"},{"key":"1903_CR6","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20140620","author":"HR Bridges","year":"2014","unstructured":"Bridges HR, Jones AJY, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 2014. https:\/\/doi.org\/10.1042\/BJ20140620.","journal-title":"Biochem J"},{"issue":"7","key":"1903_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","volume":"23","author":"H Wu","year":"2017","unstructured":"Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects. Nat Med. 2017;23(7):850\u20138. https:\/\/doi.org\/10.1038\/nm.4345.","journal-title":"Nat Med"},{"issue":"3","key":"1903_CR8","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00125-015-3844-5","volume":"59","author":"JB Buse","year":"2016","unstructured":"Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation. Diabetologia. 2016;59(3):663\u201370. https:\/\/doi.org\/10.1007\/s00125-015-3844-5.","journal-title":"Diabetologia"},{"key":"1903_CR9","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","volume":"11","author":"A Kalender","year":"2010","unstructured":"Kalender A, Selvaraj A, Kim SY, Gulati P, Br\u00fbl\u00e9 S, Viollet B. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11:390\u2013401. https:\/\/doi.org\/10.1016\/j.cmet.2010.03.014.","journal-title":"Cell Metab"},{"issue":"5","key":"1903_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1158\/1541-7786.MCR-10-0535","volume":"9","author":"Y Zhuang","year":"2011","unstructured":"Zhuang Y, Miskimins WK. Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells. Mol Cancer Res. 2011;9(5):603\u201315. https:\/\/doi.org\/10.1158\/1541-7786.MCR-10-0535.","journal-title":"Mol Cancer Res"},{"key":"1903_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3389\/fendo.2018.00658","volume":"9","author":"H Fang","year":"2018","unstructured":"Fang H, Judd RL. Metformin regulation of FGF21 signaling. Front Endocrinol (Lausanne). 2018;9:658. https:\/\/doi.org\/10.3389\/fendo.2018.00658.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"1903_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1161\/CIRCRESAHA.116.308445","volume":"119","author":"AR Cameron","year":"2016","unstructured":"Cameron AR, Morrison VL, Levin D, et al. Anti-inflammatory effects of metformin irrespective of diabetes status. Circ Res. 2016;119(5):652\u201365. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308445.","journal-title":"Circ Res"},{"key":"1903_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/790632","volume":"2014","author":"R Wahdan-Alaswad","year":"2014","unstructured":"Wahdan-Alaswad R, Edgerton SM, et al. Metformin targets glucose metabolism in triple negative breast cancer. J Oncol. 2014;2014: 790632. https:\/\/doi.org\/10.1155\/2014\/790632.","journal-title":"J Oncol"},{"key":"1903_CR14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fendo.2018.00400","volume":"9","author":"C Rotermund","year":"2018","unstructured":"Rotermund C, Machetanz G, Fitzgerald JC. The therapeutic potential of metformin in neurodegenerative diseases. Front Endocrinol (Lausanne). 2018;9:400. https:\/\/doi.org\/10.3389\/fendo.2018.00400.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"12","key":"1903_CR15","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/ph17121601","volume":"17","author":"CT Roberts","year":"2024","unstructured":"Roberts CT, Raabe N, Wiegand L, Shahib AK, Rastegar M. Diverse applications of the anti-diabetic drug metformin in treating human disease. Pharmaceuticals. 2024;17(12):1601. https:\/\/doi.org\/10.3390\/ph17121601.","journal-title":"Pharmaceuticals."},{"key":"1903_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.07.017","author":"L Yao","year":"2024","unstructured":"Yao L, Wang L, Zhang R, Soukas AA, Wu L. The direct targets of metformin in diabetes and beyond. Trends Endocrinol Metab. 2024. https:\/\/doi.org\/10.1016\/j.tem.2024.07.017.","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"1903_CR17","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1111\/dom.15759","volume":"26","author":"M Abbasi","year":"2024","unstructured":"Abbasi M, Heath B, McGinness L. Advances in metformin-delivery systems for diabetes and obesity management. Diabetes Obes Metab. 2024;26(9):3513\u201329. https:\/\/doi.org\/10.1111\/dom.15759.","journal-title":"Diabetes Obes Metab"},{"key":"1903_CR18","doi-asserted-by":"publisher","unstructured":"Aljofan M, Gaipov A. Metformin: a stroke of luck. Electron J Gen Med. 2019;16(3). https:\/\/doi.org\/10.29333\/ejgm\/108679.","DOI":"10.29333\/ejgm\/108679"},{"issue":"2","key":"1903_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1515\/jbcpp-2022-0252","volume":"34","author":"A Naseri","year":"2023","unstructured":"Naseri A, et al. Metformin: new applications for an old drug. J Basic Clin Physiol Pharmacol. 2023;34(2):151\u201360. https:\/\/doi.org\/10.1515\/jbcpp-2022-0252.","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"16","key":"1903_CR20","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.13748\/j.cnki.issn1007-7693.2020.16.019","volume":"37","author":"G Kan","year":"2020","unstructured":"Kan G, Yu J, Xiong Y. Research progress of metformin combined and chemotherapeutics in anti-tumor. Chin J Mod Appl Pharm. 2020;37(16):2025\u201330. https:\/\/doi.org\/10.13748\/j.cnki.issn1007-7693.2020.16.019.","journal-title":"Chin J Mod Appl Pharm."},{"issue":"3","key":"1903_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.18311\/jnr\/2017\/17938","volume":"17","author":"S Prabhakaran","year":"2017","unstructured":"Prabhakaran S, Thirumal D, Gimbun J, Ranganathan B. Metformin - a panacea pharmaceutical agent through convergence revolution initiative. J Nat Remedies. 2017;17(3):69\u201379. https:\/\/doi.org\/10.18311\/jnr\/2017\/17938.","journal-title":"J Nat Remedies"},{"key":"1903_CR22","doi-asserted-by":"publisher","unstructured":"Mazurek M, et al. Metformin as potential therapy for high-grade glioma. Cancers (Basel). 2020;12(1). https:\/\/doi.org\/10.3390\/cancers12010210.","DOI":"10.3390\/cancers12010210"},{"issue":"2","key":"1903_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.tips.2012.11.005","volume":"34","author":"AE Riedmaier","year":"2013","unstructured":"Riedmaier AE, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer: From the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 2013;34(2):126\u201335. https:\/\/doi.org\/10.1016\/j.tips.2012.11.005.","journal-title":"Trends Pharmacol Sci."},{"key":"1903_CR24","doi-asserted-by":"publisher","unstructured":"De A, Kuppusamy G. Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer. 2020;44(1). https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.06.003.","DOI":"10.1016\/j.currproblcancer.2019.06.003"},{"issue":"9","key":"1903_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092482","volume":"12","author":"SM Samuel","year":"2020","unstructured":"Samuel SM, Varghese E, Koklesov\u00e1 L, L\u00ed\u0161kov\u00e1 A, Kubatka P, B\u00fcsselberg D. Counteracting chemoresistance with metformin in breast cancers: targeting cancer stem cells. Cancers (Basel). 2020;12(9):1\u201352. https:\/\/doi.org\/10.3390\/cancers12092482.","journal-title":"Cancers (Basel)"},{"key":"1903_CR26","doi-asserted-by":"publisher","unstructured":"Isop LM, Neculau AE, Necula RD, Kakucs C, Moga MA, Dima L. Metformin: the winding path from understanding its molecular mechanisms to proving therapeutic benefits in neurodegenerative disorders. Pharmaceuticals. 2023;16(12). https:\/\/doi.org\/10.3390\/ph16121714.","DOI":"10.3390\/ph16121714"},{"key":"1903_CR27","doi-asserted-by":"publisher","unstructured":"Razzaq A, et al. Development and characterization of pH-responsive Delonix regia\/mucin co-poly (acrylate) hydrogel for controlled drug delivery of metformin HCl. Int J Biol Macromol. 2024;274. https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.132767.","DOI":"10.1016\/j.ijbiomac.2024.132767"},{"key":"1903_CR28","doi-asserted-by":"publisher","unstructured":"Yang J, et al. Recent progress in microneedles-mediated diagnosis, therapy, and theranostic systems. Adv Healthc Mater. 2022;11(10). https:\/\/doi.org\/10.1002\/adhm.202102547.","DOI":"10.1002\/adhm.202102547"},{"key":"1903_CR29","unstructured":"Kitchenham B. Guidelines for performing systematic literature reviews in software engineering. Tech Rep, Ver. 2.3 EBSE Tech Rep EBSE. 2007."},{"issue":"3","key":"1903_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/XEB.0000000000000062","volume":"13","author":"C Lockwood","year":"2015","unstructured":"Lockwood C, Munn Z, Porritt K. Qualitative research synthesis: Methodological guidance for systematic reviewers utilizing meta-aggregation. Int J Evid Based Healthc. 2015;13(3):179\u201387. https:\/\/doi.org\/10.1097\/XEB.0000000000000062.","journal-title":"Int J Evid Based Healthc"},{"issue":"4","key":"1903_CR31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.21860\/medflum2021_264903","volume":"57","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The prisma 2020 statement: an updated guideline for reporting systematic reviews. Med Flum. 2021;57(4):444\u201365. https:\/\/doi.org\/10.21860\/medflum2021_264903.","journal-title":"Med Flum."},{"key":"1903_CR32","doi-asserted-by":"publisher","unstructured":"Abouzahra A, Sabraoui A, Afdel K. Model composition in model driven engineering: a systematic literature review. Elsevier B.V. 2020;. https:\/\/doi.org\/10.1016\/j.infsof.2020.106316.","DOI":"10.1016\/j.infsof.2020.106316"},{"issue":"4","key":"1903_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.3390\/ph15040442","volume":"15","author":"AEY Chow","year":"2022","unstructured":"Chow AEY, Chung CHL, Chan JCN. A Clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer. Pharmaceuticals. 2022;15(4):442. https:\/\/doi.org\/10.3390\/ph15040442.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"1903_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.14740\/jocmr2922e","volume":"9","author":"E Abdelgadir","year":"2017","unstructured":"Abdelgadir E, Ali R, Rashid F, Bashier A. Effect of metformin on different non-diabetes related conditions, a special focus on malignant conditions: review of literature. J Clin Med Res. 2017;9(5):388. https:\/\/doi.org\/10.14740\/jocmr2922e.","journal-title":"J Clin Med Res"},{"key":"1903_CR35","doi-asserted-by":"publisher","unstructured":"Wang Z, Olumi AF. Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease? AJP Ren Physiol. 2017;314(3). https:\/\/doi.org\/10.1152\/ajprenal.00443.2017","DOI":"10.1152\/ajprenal.00443.2017"},{"key":"1903_CR36","doi-asserted-by":"publisher","unstructured":"Song CW, Lee H, Dings RPM, Williams B, Powers J, Dos Santos T, Choi B-H, Park HJ. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012;2. https:\/\/doi.org\/10.1038\/srep00362","DOI":"10.1038\/srep00362"},{"issue":"26","key":"1903_CR37","doi-asserted-by":"publisher","first-page":"40767","DOI":"10.18632\/oncotarget.8194","volume":"7","author":"YK Chae","year":"2016","unstructured":"Chae YK, Arya A, Malecek M-K, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(26):40767. https:\/\/doi.org\/10.18632\/oncotarget.8194.","journal-title":"Oncotarget."},{"key":"1903_CR38","doi-asserted-by":"publisher","unstructured":"Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Alves APNR, Scheucher PS, Sim\u00f5es BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death Dis. 2018;9(3). https:\/\/doi.org\/10.1038\/s41419-017-0256-4","DOI":"10.1038\/s41419-017-0256-4"},{"key":"1903_CR39","doi-asserted-by":"publisher","unstructured":"P Saraei, I Kakar, MA Moradikor, Moradi-Kor N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag Res. 2019;3295, https:\/\/doi.org\/10.2147\/cmar.s200059","DOI":"10.2147\/cmar.s200059"},{"key":"1903_CR40","doi-asserted-by":"publisher","unstructured":"Hua Y, Zheng Y, Yao Y, Jia R, Ge S, Zhuang A. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing. J Transl Med. 2023;21(1). https:\/\/doi.org\/10.1186\/s12967-023-04263-8","DOI":"10.1186\/s12967-023-04263-8"},{"key":"1903_CR41","doi-asserted-by":"publisher","unstructured":"Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol. 2012;63(4):709. https:\/\/doi.org\/10.1016\/j.eururo.2012.12.004","DOI":"10.1016\/j.eururo.2012.12.004"},{"key":"1903_CR42","doi-asserted-by":"publisher","unstructured":"Vial G, Detaille D, Guigas B. Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol (Lausanne). 2019;10. https:\/\/doi.org\/10.3389\/fendo.2019.00294","DOI":"10.3389\/fendo.2019.00294"},{"issue":"2","key":"1903_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/fjc.0000000000000599","volume":"72","author":"C Driver","year":"2018","unstructured":"Driver C, Bamitale KD, Kazi A, Olla M, Nyane NA, Owira PM. Cardioprotective effects of metformin. J Cardiovasc Pharmacol. 2018;72(2):121. https:\/\/doi.org\/10.1097\/fjc.0000000000000599.","journal-title":"J Cardiovasc Pharmacol."},{"issue":"8","key":"1903_CR44","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","volume":"27","author":"L Nesti","year":"2017","unstructured":"Nesti L, Natali A. Metformin effects on the heart and the cardiovascular system: a review of experimental and clinical data. Nutr Metab Cardiovasc Dis. 2017;27(8):657. https:\/\/doi.org\/10.1016\/j.numecd.2017.04.009.","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"3","key":"1903_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/1871530315666150316124019","volume":"15","author":"Y Saisho","year":"2015","unstructured":"Saisho Y. Metformin and inflammation: its potential beyond glucose-lowering effect. Endocrine Metab Immune Disord-Drug Targets. 2015;15(3):196\u2013205. https:\/\/doi.org\/10.2174\/1871530315666150316124019.","journal-title":"Endocrine Metab Immune Disord-Drug Targets"},{"issue":"6","key":"1903_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/cs20110386","volume":"122","author":"B Viollet","year":"2011","unstructured":"Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci. 2011;122(6):253. https:\/\/doi.org\/10.1042\/cs20110386.","journal-title":"Clin Sci."},{"key":"1903_CR47","doi-asserted-by":"publisher","first-page":"155160","DOI":"10.1016\/j.metabol.2022.155160","volume":"130","author":"G Schernthaner","year":"2022","unstructured":"Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism. 2022;130:155160. https:\/\/doi.org\/10.1016\/j.metabol.2022.155160.","journal-title":"Metabolism"},{"issue":"19","key":"1903_CR48","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1111\/jcmm.17519","volume":"26","author":"Y Bu","year":"2022","unstructured":"Bu Y, Peng M, Tang X, Xu X, Wu Y, Chen AF, Yang X. Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms. J Cell Mol Med. 2022;26(19):4886. https:\/\/doi.org\/10.1111\/jcmm.17519.","journal-title":"J Cell Mol Med."},{"issue":"19","key":"1903_CR49","doi-asserted-by":"publisher","first-page":"9376","DOI":"10.7150\/thno.64706","volume":"11","author":"Y Ding","year":"2021","unstructured":"Ding Y, Zhou Y, Ling P, Feng X, Luo S, Zheng X, Little PJ, Xu S, Weng J. Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics. 2021;11(19):9376. https:\/\/doi.org\/10.7150\/thno.64706.","journal-title":"Theranostics"},{"issue":"1","key":"1903_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","volume":"137","author":"D Kirpichnikov","year":"2002","unstructured":"Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25. https:\/\/doi.org\/10.7326\/0003-4819-137-1-200207020-00009.","journal-title":"Ann Intern Med."},{"issue":"2","key":"1903_CR51","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/ph14020122","volume":"14","author":"J Drzewoski","year":"2021","unstructured":"Drzewoski J, Hanefeld M. The current and potential therapeutic use of metformin\u2014the good old drug. Pharmaceuticals. 2021;14(2):122. https:\/\/doi.org\/10.3390\/ph14020122.","journal-title":"Pharmaceuticals"},{"issue":"12","key":"1903_CR52","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1016\/s0149-2918(03)90089-0","volume":"25","author":"SM Setter","year":"2003","unstructured":"Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther. 2003;25(12):2991. https:\/\/doi.org\/10.1016\/s0149-2918(03)90089-0.","journal-title":"Clin Ther."},{"key":"1903_CR53","doi-asserted-by":"publisher","unstructured":"Luo F, Das A, Chen J, Wu P, Li X, Fang Z. Metformin in patients with and without diabetes: a paradigm shift in cardiovascular disease management. Cardiovasc Diabetol. 2019;18(1). https:\/\/doi.org\/10.1186\/s12933-019-0860-y","DOI":"10.1186\/s12933-019-0860-y"},{"issue":"8","key":"1903_CR54","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"M Foretz","year":"2023","unstructured":"Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023;19(8):460. https:\/\/doi.org\/10.1038\/s41574-023-00833-4.","journal-title":"Nat Rev Endocrinol."},{"issue":"7","key":"1903_CR55","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1517\/14728222.2015.1025051","volume":"19","author":"R Ladeiras-Lopes","year":"2015","unstructured":"Ladeiras-Lopes R, Bettencourt N, Sampaio F, Gama V, Leite-Moreira A. Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease. Expert Opin Ther Targets. 2015;19(7):869. https:\/\/doi.org\/10.1517\/14728222.2015.1025051.","journal-title":"Expert Opin. Ther. Targets"},{"issue":"19","key":"1903_CR56","doi-asserted-by":"publisher","first-page":"10275","DOI":"10.3390\/ijms221910275","volume":"22","author":"HW Kim","year":"2021","unstructured":"Kim HW. Metabolomic approaches to investigate the effect of metformin: an overview. Int J Mol Sci. 2021;22(19):10275. https:\/\/doi.org\/10.3390\/ijms221910275.","journal-title":"Int J Mol Sci."},{"key":"1903_CR57","doi-asserted-by":"publisher","unstructured":"Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9(1). https:\/\/doi.org\/10.1186\/1741-7015-9-33.","DOI":"10.1186\/1741-7015-9-33"},{"key":"1903_CR58","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305-5839.2014.06.01","author":"J Kasznicki","year":"2014","unstructured":"Kasznicki J, \u015aliwi\u0144ska A, Drzewoski J. Metformin in cancer prevention and therapy. PubMed. 2014. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2014.06.01.","journal-title":"PubMed"},{"key":"1903_CR59","doi-asserted-by":"publisher","unstructured":"Du MR, Gao QY, Liu CL, Bai LY, Li T, Wei FL. Exploring the pharmacological potential of metformin for neurodegenerative diseases. Front Aging Neurosci. 2022;14. https:\/\/doi.org\/10.3389\/fnagi.2022.838173.","DOI":"10.3389\/fnagi.2022.838173"},{"issue":"7899","key":"1903_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","volume":"603","author":"T Ma","year":"2022","unstructured":"Ma T, et al. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature. 2022;603(7899):159. https:\/\/doi.org\/10.1038\/s41586-022-04431-8.","journal-title":"Nature"},{"key":"1903_CR61","doi-asserted-by":"publisher","unstructured":"Hidayat ST, Mulyantoro I, Damas S, Tjandrawinata RR. The effect and safety assessment of metformin and DLBS3233 (A Bioactive Fraction of Lagerstroemia speciosa and Cinnamomum burmannii) on improving metabolic parameters in women with polycystic ovary syndrome. Int J Womens Health. 2023;971. https:\/\/doi.org\/10.2147\/ijwh.s409685.","DOI":"10.2147\/ijwh.s409685"},{"issue":"1","key":"1903_CR62","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0002-9343(96)00353-1","volume":"102","author":"MB Davidson","year":"1997","unstructured":"Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99. https:\/\/doi.org\/10.1016\/s0002-9343(96)00353-1.","journal-title":"Am J Med"},{"key":"1903_CR63","doi-asserted-by":"publisher","unstructured":"Zhao B, et al. Metformin suppresses self-renewal ability and tumorigenicity of osteosarcoma stem cells via reactive oxygen species-mediated apoptosis and autophagy. Oxid Med Cell Longev. 2019;2019. https:\/\/doi.org\/10.1155\/2019\/9290728.","DOI":"10.1155\/2019\/9290728"},{"key":"1903_CR64","doi-asserted-by":"publisher","unstructured":"Huang F, et al. Metformin and MiR-365 synergistically promote the apoptosis of gastric cancer cells via MiR-365-PTEN-AMPK axis. Pathol Res Pract. 2022;230. https:\/\/doi.org\/10.1016\/j.prp.2021.153740.","DOI":"10.1016\/j.prp.2021.153740"},{"issue":"3","key":"1903_CR65","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/andr.12755","volume":"8","author":"Y Yang","year":"2020","unstructured":"Yang Y, et al. In vitro exposure to metformin activates human spermatozoa at therapeutically relevant concentrations. Andrology. 2020;8(3):663\u201370. https:\/\/doi.org\/10.1111\/andr.12755.","journal-title":"Andrology"},{"key":"1903_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110012","volume":"144","author":"Z Karadeniz","year":"2020","unstructured":"Karadeniz Z, Aynac\u0131o\u011flu A\u015e, Bilir A, Tuna MY. Inhibition of midkine by Metformin can contribute to its anticancer effects in malignancies: a proposed mechanism in endometrial cancer prevention and therapy. Med Hypotheses. 2020;144: 110012. https:\/\/doi.org\/10.1016\/j.mehy.2020.110012.","journal-title":"Med Hypotheses"},{"key":"1903_CR67","doi-asserted-by":"publisher","unstructured":"Ailuno G, et al. Development of biotinylated liposomes encapsulating metformin for therapeutic targeting of inflammation-based diseases. Pharmaceutics. 2024;16(2). https:\/\/doi.org\/10.3390\/pharmaceutics16020235.","DOI":"10.3390\/pharmaceutics16020235"},{"issue":"3","key":"1903_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10030681","volume":"10","author":"HS Na","year":"2021","unstructured":"Na HS, et al. Metformin attenuates monosodium-iodoacetate-induced osteoarthritis via regulation of pain mediators and the autophagy\u2013lysosomal pathway. Cells. 2021;10(3):1\u201315. https:\/\/doi.org\/10.3390\/cells10030681.","journal-title":"Cells"},{"key":"1903_CR69","doi-asserted-by":"publisher","unstructured":"Yi H, et al. Metformin attenuates renal fibrosis in a mouse model of adenine-induced renal injury through inhibiting TGF-\u03b21 signaling pathways. Front Cell Dev Biol. 2021;9. https:\/\/doi.org\/10.3389\/fcell.2021.603802.","DOI":"10.3389\/fcell.2021.603802"},{"issue":"2","key":"1903_CR70","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FJC.0000000000000599","volume":"72","author":"C Driver","year":"2018","unstructured":"Driver C, Bamitale KDS, Kazi A, Olla M, Nyane NA, Owira PMO. Cardioprotective effects of metformin. J Cardiovasc Pharmacol. 2018;72(2):121\u20137. https:\/\/doi.org\/10.1097\/FJC.0000000000000599.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"1903_CR71","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1007\/s11033-020-05582-5","volume":"47","author":"SM El Kiki","year":"2020","unstructured":"El Kiki SM, Omran MM, Mansour HH, Hasan HF. Metformin and\/or low dose radiation reduces cardiotoxicity and apoptosis induced by cyclophosphamide through SIRT-1\/SOD and BAX\/Bcl-2 pathways in rats. Mol Biol Rep. 2020;47(7):5115\u201326. https:\/\/doi.org\/10.1007\/s11033-020-05582-5.","journal-title":"Mol Biol Rep."},{"key":"1903_CR72","doi-asserted-by":"publisher","unstructured":"Kodali M, et al. Metformin treatment in late middle age improves cognitive function with alleviation of microglial activation and enhancement of autophagy in the hippocampus. Aging Cell. 2021;20(2). https:\/\/doi.org\/10.1111\/acel.13277.","DOI":"10.1111\/acel.13277"},{"issue":"10","key":"1903_CR73","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","volume":"75","author":"U Hostalek","year":"2015","unstructured":"Hostalek U, Gwilt M, Hildemann S. Therapeutic use of metformin in prediabetes and diabetes prevention. Drugs. 2015;75(10):1071\u201394. https:\/\/doi.org\/10.1007\/s40265-015-0416-8.","journal-title":"Drugs"},{"key":"1903_CR74","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.phrs.2015.07.014","volume":"100","author":"A Diot","year":"2015","unstructured":"Diot A, et al. A novel quantitative assay of mitophagy: Combining high content fluorescence microscopy and mitochondrial DNA load to quantify mitophagy and identify novel pharmacological tools against pathogenic heteroplasmic mtDNA. Pharmacol Res. 2015;100:24\u201335. https:\/\/doi.org\/10.1016\/j.phrs.2015.07.014.","journal-title":"Pharmacol Res"},{"key":"1903_CR75","doi-asserted-by":"publisher","unstructured":"Chen J, Ou Y, Li Y, Hu S, Shao LW, Liu Y. Metformin extends C. Elegans lifespan through lysosomal pathway. Elife. 2017;6. https:\/\/doi.org\/10.7554\/eLife.31268.","DOI":"10.7554\/eLife.31268"},{"key":"1903_CR76","doi-asserted-by":"publisher","unstructured":"Xiao Y, et al. Metformin induces S-adenosylmethionine restriction to extend the Caenorhabditis elegans healthspan through H3K4me3 modifiers. Aging Cell. 2022;21(3). https:\/\/doi.org\/10.1111\/acel.13567.","DOI":"10.1111\/acel.13567"},{"key":"1903_CR77","doi-asserted-by":"publisher","unstructured":"Triggle CR, et al. Metformin: is it a drug for all reasons and diseases? Metabolism. 2022;133. https:\/\/doi.org\/10.1016\/j.metabol.2022.155223.","DOI":"10.1016\/j.metabol.2022.155223"},{"key":"1903_CR78","doi-asserted-by":"publisher","unstructured":"Viollet B, Guigas B, Garcia NS, Leclerc J, Foretz M, Andr\u00e9elli F. Cellular and molecular mechanisms of metformin: an overview. 2011; Portland Press. https:\/\/doi.org\/10.1042\/cs20110386.","DOI":"10.1042\/cs20110386"},{"key":"1903_CR79","doi-asserted-by":"publisher","unstructured":"Du Y, Zhu Y, Zhou Y, Ding J, Liu J. Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study. 2022; Springer Nature. https:\/\/doi.org\/10.1186\/s43556-022-00108-w.","DOI":"10.1186\/s43556-022-00108-w"},{"key":"1903_CR80","doi-asserted-by":"publisher","unstructured":"Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. 2002. https:\/\/doi.org\/10.7326\/0003-4819-137-1-200207020-00009.","DOI":"10.7326\/0003-4819-137-1-200207020-00009"},{"issue":"7","key":"1903_CR81","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1007\/s10238-023-01051-y","volume":"23","author":"H Zhu","year":"2023","unstructured":"Zhu H, Jia Z, Li YR, Danelisen I. Molecular mechanisms of action of metformin: latest advances and therapeutic implications. Clin Exp Med. 2023;23(7):2941\u201351. https:\/\/doi.org\/10.1007\/s10238-023-01051-y.","journal-title":"Clin Exp Med"},{"key":"1903_CR82","doi-asserted-by":"publisher","unstructured":"Leverve X, et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. 2003; Elsevier BV. https:\/\/doi.org\/10.1016\/s1262-3636(03)72792-x.","DOI":"10.1016\/s1262-3636(03)72792-x"},{"key":"1903_CR83","doi-asserted-by":"publisher","unstructured":"Hur KY, Lee M. New mechanisms of metformin action: Focusing on mitochondria and the gut. 2015; Asian Association for the Study of Diabetes. https:\/\/doi.org\/10.1111\/jdi.12328.","DOI":"10.1111\/jdi.12328"},{"key":"1903_CR84","doi-asserted-by":"publisher","unstructured":"Vial G, Detaille D, Guigas B. Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol (Lausanne). 2019;10(MAY). https:\/\/doi.org\/10.3389\/fendo.2019.00294.","DOI":"10.3389\/fendo.2019.00294"},{"key":"1903_CR85","doi-asserted-by":"publisher","unstructured":"Fontaine E. Metformin-induced mitochondrial complex I inhibition: facts, uncertainties, and consequences. Front Endocrinol (Lausanne). 2018;9. https:\/\/doi.org\/10.3389\/fendo.2018.00753.","DOI":"10.3389\/fendo.2018.00753"},{"key":"1903_CR86","doi-asserted-by":"publisher","unstructured":"Wheaton WW, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3. https:\/\/doi.org\/10.7554\/elife.02242.","DOI":"10.7554\/elife.02242"},{"key":"1903_CR87","doi-asserted-by":"publisher","unstructured":"Yu H, Zheng Y, Yao Y, Jia R, Ge S, Zhuang A. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing. 2023, BioMed Central. https:\/\/doi.org\/10.1186\/s12967-023-04263-8.","DOI":"10.1186\/s12967-023-04263-8"},{"key":"1903_CR88","doi-asserted-by":"publisher","unstructured":"Hardie DG, Ross FA, Hawley SA. AMP-activated protein kinase: a target for drugs both ancient and modern. 2012, Elsevier BV. https:\/\/doi.org\/10.1016\/j.chembiol.2012.08.019.","DOI":"10.1016\/j.chembiol.2012.08.019"},{"issue":"12","key":"1903_CR89","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/ph17121601","volume":"17","author":"JD Smith","year":"2024","unstructured":"Smith JD, Matthews LC. Metformin: mechanisms of action and repurposing for therapeutic applications. Pharmaceuticals. 2024;17(12):1601. https:\/\/doi.org\/10.3390\/ph17121601.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"1903_CR90","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41574-023-00833-4","volume":"19","author":"JH Lory","year":"2023","unstructured":"Lory JH, Keating SJ, Inzucchi SE. The complex role of metformin in diabetes treatment and beyond. Nat Rev Endocrinol. 2023;19(10):601\u201312. https:\/\/doi.org\/10.1038\/s41574-023-00833-4.","journal-title":"Nat Rev Endocrinol"},{"key":"1903_CR91","doi-asserted-by":"publisher","unstructured":"Song CW, et al. Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep. 2012;2(1). https:\/\/doi.org\/10.1038\/srep00362.","DOI":"10.1038\/srep00362"},{"key":"1903_CR92","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1210\/en.2012-1145","volume":"153","author":"A Hirsch","year":"2012","unstructured":"Hirsch A, et al. Metformin inhibits human androgen production by regulating steroidogenic enzymes HSD3B2 and CYP17A1 and complex I activity of the respiratory chain. Endocrinology. 2012;153:4354\u201366. https:\/\/doi.org\/10.1210\/en.2012-1145.","journal-title":"Endocrinology"},{"key":"1903_CR93","doi-asserted-by":"publisher","unstructured":"Cao H et al. Metformin enhances the therapy effects of anti-IGF-1R mAb Figitumumab to NSCLC. Sci Rep. 2016;6. https:\/\/doi.org\/10.1038\/srep31072.","DOI":"10.1038\/srep31072"},{"issue":"11","key":"1903_CR94","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1517\/13543784.2013.828691","volume":"22","author":"F Morgillo","year":"2013","unstructured":"Morgillo F, et al. Metformin in lung cancer: rationale for a combination therapy. Expert Opin Investig Drugs. 2013;22(11):1401. https:\/\/doi.org\/10.1517\/13543784.2013.828691.","journal-title":"Expert Opin Investig Drugs"},{"issue":"5","key":"1903_CR95","first-page":"880","volume":"9","author":"AB De Oliveira","year":"2019","unstructured":"De Oliveira AB, Bock PM, Leal DR. Nanotechnology-based drug delivery systems for metformin: a promising strategy for cancer treatment. Drug Deliv Transl Res. 2019;9(5):880\u201390.","journal-title":"Drug Deliv Transl Res"},{"key":"1903_CR96","doi-asserted-by":"crossref","first-page":"119543","DOI":"10.1016\/j.ijpharm.2020.119518","volume":"586","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chen Z, Han Y. Nanocarriers for enhancing oral bioavailability of metformin. Int J Pharm. 2020;586:119543.","journal-title":"Int J Pharm"},{"key":"1903_CR97","first-page":"106460","volume":"185","author":"V Ghorbanzadeh","year":"2023","unstructured":"Ghorbanzadeh V, Mohammadi A, Badr P. Targeted delivery of metformin via nanocarriers: current strategies and future prospects. Eur J Pharm Sci. 2023;185:106460.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1903_CR98","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/pharmaceutics16010152","volume":"16","author":"E Amengual-Cladera","year":"2024","unstructured":"Amengual-Cladera E, Roca P, Alemany M. Lipid-based and polymeric nanocarriers for improved metformin delivery: implications in metabolic and inflammatory diseases. Pharmaceutics. 2024;16(1):152.","journal-title":"Pharmaceutics"},{"issue":"9","key":"1903_CR99","first-page":"952","volume":"28","author":"Y Huang","year":"2020","unstructured":"Huang Y, Wang Z, Ma Z. Recent advances in nanoparticle-based systems for metformin delivery. J Drug Target. 2020;28(9):952\u201361.","journal-title":"J Drug Target"},{"issue":"1","key":"1903_CR100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ajps.2020.05.001","volume":"16","author":"YV Simos","year":"2020","unstructured":"Simos YV, et al. Trends of nanotechnology in type 2 diabetes mellitus treatment. Asian J Pharm Sci. 2020;16(1):62. https:\/\/doi.org\/10.1016\/j.ajps.2020.05.001.","journal-title":"Asian J Pharm Sci"},{"issue":"24","key":"1903_CR101","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.3390\/nano12244494","volume":"12","author":"O Afzal","year":"2022","unstructured":"Afzal O, et al. Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials. 2022;12(24):4494. https:\/\/doi.org\/10.3390\/nano12244494.","journal-title":"Nanomaterials"},{"key":"1903_CR102","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11244-022-01770-8","volume":"66","author":"I Batool","year":"2023","unstructured":"Batool I, Iqbal A, Imran M, Ramzan M, Anwar A. Design and applications of enzyme-linked nanostructured materials for efficient bio-catalysis. Top Catal. 2023;66:649. https:\/\/doi.org\/10.1007\/s11244-022-01770-8.","journal-title":"Top Catal"},{"key":"1903_CR103","first-page":"114029","volume":"200","author":"J Melin","year":"2023","unstructured":"Melin J, Zhao F, Tang J. Functionalization strategies in nanocarrier-based drug delivery: optimizing selectivity and therapeutic index. Adv Drug Deliv Rev. 2023;200:114029.","journal-title":"Adv Drug Deliv Rev"},{"key":"1903_CR104","doi-asserted-by":"publisher","unstructured":"Szewczuk MR. Advancements in polymer science: \u2018Smart\u2019 drug delivery systems for the treatment of cancer. MOJ Polym Sci. 2017;1(3). https:\/\/doi.org\/10.15406\/mojps.2017.01.00016.","DOI":"10.15406\/mojps.2017.01.00016"},{"issue":"3","key":"1903_CR105","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/nano12030457","volume":"12","author":"V Harish","year":"2022","unstructured":"Harish V, et al. Review on nanoparticles and nanostructured materials: bioimaging, biosensing, drug delivery, tissue engineering, antimicrobial, and agro-food applications. Nanomaterials. 2022;12(3):457. https:\/\/doi.org\/10.3390\/nano12030457.","journal-title":"Nanomaterials"},{"key":"1903_CR106","doi-asserted-by":"publisher","unstructured":"Chen Y, et al. Adjunctive probio-X treatment enhances the therapeutic effect of a conventional drug in managing type 2 diabetes mellitus by promoting short-chain fatty acid-producing bacteria and bile acid pathways. mSystems. 2023;8(1). https:\/\/doi.org\/10.1128\/msystems.01300-22.","DOI":"10.1128\/msystems.01300-22"},{"issue":"3","key":"1903_CR107","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5530\/pj.2021.13.98","volume":"13","author":"N Choudhary","year":"2021","unstructured":"Choudhary N, Prabhakar PK, Khatik GL, Chamakuri SR, Tewari D, Suttee A. Evaluation of acute toxicity, in-vitro, in-vivo antidiabetic potential of the flavonoid fraction of the plant chenopodium album L. Pharmacogn J. 2021;13(3):765. https:\/\/doi.org\/10.5530\/pj.2021.13.98.","journal-title":"Pharmacogn J."},{"issue":"3","key":"1903_CR108","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2174\/157016110791112359","volume":"8","author":"G Anfossi","year":"2010","unstructured":"Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2010;8(3):327. https:\/\/doi.org\/10.2174\/157016110791112359.","journal-title":"Curr Vasc Pharmacol"},{"issue":"18","key":"1903_CR109","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.3390\/ijms20184331","volume":"20","author":"L Pinzi","year":"2019","unstructured":"Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019;20(18):4331. https:\/\/doi.org\/10.3390\/ijms20184331.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1903_CR110","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/molecules28093906","volume":"28","author":"D Bassani","year":"2023","unstructured":"Bassani D, Moro S. Past, present, and future perspectives on computer-aided drug design methodologies. Molecules. 2023;28(9):3906. https:\/\/doi.org\/10.3390\/molecules28093906.","journal-title":"Molecules"},{"key":"1903_CR111","doi-asserted-by":"publisher","unstructured":"Shaker B, Ahmad S, Lee J, Jung C, Na D. In silico methods and tools for drug discovery. 2021. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104851.","DOI":"10.1016\/j.compbiomed.2021.104851"},{"key":"1903_CR112","doi-asserted-by":"publisher","DOI":"10.1007\/s12010-024-05110-2","author":"HO Rasul","year":"2024","unstructured":"Rasul HO, Ghafour DD, Aziz BK, Hassan BA, Rashid TA, K\u0131vrak A. Decoding drug discovery: exploring A-to-Z in silico methods for beginners. Appl Biochem Biotechnol. 2024. https:\/\/doi.org\/10.1007\/s12010-024-05110-2.","journal-title":"Appl Biochem Biotechnol"},{"key":"1903_CR113","doi-asserted-by":"publisher","unstructured":"Cui W, Aouidate A, Wang S, Yu Q, Li Y-H, Yuan S. Discovering anti-cancer drugs via computational methods. Front Pharmacol. 2020;11. https:\/\/doi.org\/10.3389\/fphar.2020.00733.","DOI":"10.3389\/fphar.2020.00733"},{"issue":"7","key":"1903_CR114","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3390\/pharmaceutics15071916","volume":"15","author":"LK Vora","year":"2023","unstructured":"Vora LK, Gholap AD, Jetha K, Singh TRR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916. https:\/\/doi.org\/10.3390\/pharmaceutics15071916.","journal-title":"Pharmaceutics"},{"key":"1903_CR115","doi-asserted-by":"publisher","first-page":"134419","DOI":"10.1016\/j.chemosphere.2022.134419","volume":"299","author":"A de Oliveira Maciel","year":"2022","unstructured":"de Oliveira Maciel A, Christakopoulos P, Rova U, Antonopoulou I. Carbonic anhydrase to boost CO2 sequestration: Improving carbon capture utilization and storage (CCUS). Chemosphere. 2022;299:134419. https:\/\/doi.org\/10.1016\/j.chemosphere.2022.134419.","journal-title":"Chemosphere"},{"key":"1903_CR116","doi-asserted-by":"publisher","unstructured":"Nguyen TT, et al. Artificial intelligence in the battle against coronavirus (COVID-19): a survey and future research directions. Cornell Univ. 2020. https:\/\/doi.org\/10.48550\/arxiv.2008.07343.","DOI":"10.48550\/arxiv.2008.07343"},{"key":"1903_CR117","doi-asserted-by":"publisher","unstructured":"Machado\u2010Neto JA, et al. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death Dis. 2018;9(3). https:\/\/doi.org\/10.1038\/s41419-017-0256-4.","DOI":"10.1038\/s41419-017-0256-4"},{"issue":"3","key":"1903_CR118","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2337\/dc20-1964","volume":"44","author":"A Giaccari","year":"2021","unstructured":"Giaccari A, Solini A, Frontoni S, Prato SD. Metformin benefits: another example for alternative energy substrate mechanism? Diabetes Care. 2021;44(3):647. https:\/\/doi.org\/10.2337\/dc20-1964.","journal-title":"Diabetes Care"},{"issue":"1","key":"1903_CR119","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/ijms26010364","volume":"26","author":"J Yip","year":"2025","unstructured":"Yip J, et al. Mitochondria and the repurposing of diabetes drugs for off-label health benefits. Int J Mol Sci. 2025;26(1):364. https:\/\/doi.org\/10.3390\/ijms26010364.","journal-title":"Int J Mol Sci"},{"key":"1903_CR120","doi-asserted-by":"publisher","unstructured":"Chow E, Yang A, Chung CHL, Chan JCN. A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer. 2022;. Multidisciplinary Digital Publishing Institute. https:\/\/doi.org\/10.3390\/ph15040442.","DOI":"10.3390\/ph15040442"},{"issue":"11","key":"1903_CR121","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1080\/03639045.2019.1665060","volume":"45","author":"A De","year":"2019","unstructured":"De A, Kuppuswamy G, Jaiswal A. Implementation of two different experimental designs for screening and optimization of process parameters for metformin-loaded carboxymethyl chitosan formulation. Drug Dev Ind Pharm. 2019;45(11):1821\u201334. https:\/\/doi.org\/10.1080\/03639045.2019.1665060.","journal-title":"Drug Dev Ind Pharm"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01903-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01903-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01903-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T13:00:36Z","timestamp":1759928436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01903-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":121,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1903"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01903-y","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"assertion":[{"value":"15 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review paper and does not involve collecting primary data from participants or human or animal subjects. Therefore, ethics approval and consent to participate are not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This article is a review paper and does not involve the collection of primary data or personal information from participants. Therefore, consent for publication is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. None of the authors has received any financial or other benefits from organizations that could gain or lose financially through the publication of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}